期刊文献+

通过移动技术实现多中心用药指南遵从性干预研究

The Multicenter Intervention Research on Drug Use Guide Compliance Based on Mobile Technology
下载PDF
导出
摘要 目的:针对我国临床医师二级预防用药指南遵从性不足问题,进行跨区域多医院干预,以提高医师用药指南遵从性。方法:在全国范围内三十家医院开展,通过移动技术从中心、医院、临床医生三个层面进行干预。结果:参与医院总体二级预防用药指南遵从性高于去年同期水平。结论:通过移动技术有效改善了多中心用药指南遵从性,为进行跨区域多医院的临床干预提出了新思路。 Objective: In view of the secondary prevention medication guide clinicians lack of compliance issues, cross-regional multihospital interventions to improve physician medication guide compliance. Methods: Launched in 30 hospitals nationwide, intervene in centers, hospitals and clinicians three different levels by mobile technologies. Results: The overall secondary prevention medication guide compliance of those collaboration hospitals is higher than last year. Conclusion: The multi-center medication guide compliance is improved by using mobile technologies. And new ideas for cross-regional multi-hospital clinical interventions are developed.
出处 《中国数字医学》 2016年第5期18-19,30,共3页 China Digital Medicine
基金 十二五国家科技支撑计划-心血管疾病关键治疗技术临床多中心研究信息平台(编号:2011BAI11B02)~~
关键词 移动技术 智能手机 二级预防用药 指南遵从性 mobile technology smart phone secondary prevention drug use guide compliance
  • 相关文献

参考文献5

二级参考文献36

  • 1Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation, 2015, 131: 927-964.
  • 2Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on ractice Guidelines. Developed ineollahoration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2011, 58: e123-210.
  • 3Smith SC Jr, Benjamin E J, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atheroseleroticvaseular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol, 2011, 58: 2432-2446.
  • 4Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Cardiac Surg, 2013, 28:109-116.
  • 5Brilakis ES, de Lemos JA, Cannon CP, et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the pravastatin or atorvastatin evaluation and infection therapy [prove it-timi 22] and the aggrastat to zocor [a to z] trials). Am J Cardiol, 2008, 102: 552-558.
  • 6Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended- release niacin with laropiprant in high-risk patients. N Engl J Med, 2014, 371: 203-212.
  • 7Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 1985, 27: 335-371.
  • 8Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med, 1998, 339: 489-497.
  • 9Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coil Cardiol, 2007, 50: 563-572.
  • 10Zhang H, Yuan X, Zhang H, et al. Efficacy of long-term beta-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery. Circulation, 2015, 131: 2194-2201.

共引文献144

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部